ensitrelvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 5727 | 2647530-73-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ensitrelvir is an orally active 3C-like protease inhibitor and it was approved for emergency use in Japan in November 2022. Ensitrelvir has reached Phase III clinical trials and is being evaluated for its efficacy and safety in patients with mild-to-moderate COVID-19.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 22, 2022 | PMDA | Shionogi & Co., Ltd. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Disease caused by Severe acute respiratory syndrome coronavirus 2 | indication | 840539006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Enzyme | INHIBITOR | IC50 | 7.31 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 7YY | PDB_CHEM_ID |
| C000722354 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11871 | IUPHAR_LIGAND_ID |
| C5690425 | UMLSCUI |
| 12284 | INN_ID |
| 2757470-18-9 | SECONDARY_CAS_RN |
| 162533924 | PUBCHEM_CID |
| D12619 | KEGG_DRUG |
| PX665RAA3H | UNII |
Pharmaceutical products:
None